[1] Abaji, R., & Krajinovic, M. (2017). Thiopurine Smethyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: Influence on treatment response. Pharmacogenomics Pers Med, 10, 143– 156.

[2] Ames, M. M., Selassie, C. D., Woodson, L. C., Loon, J. A. V., Hansch, C., & Weinshilboum, R. M. (2002). ACS publications. American Chemical Society.

[3] Ameyaw, M. M., Collie-Duguid, E. S., Powrie, R. H., Ofori-Adjei, D., & McLeod, H. L. (1999). Thiopurine methyltransferase alleles in British and Ghanaian populations. Human Molecular Genetics, 8(2), 367– 370. https://doi.org/10.1093/hmg/8.2.367

[4] Ansari, A. (2003). Treatment of zero and intermediate TPMT patients with a tailored dose of azathioprine - Research Portal. King’s College.

[5] Azad, M., Kaviani, S., Soleymani, M., Nourouzinia, M., & Hajfathali A. (2009). Common polymorphism’s analysis of thiopurine S-methyltransferase (TPMT) in Iranian population. Yakhteh Medical Journal, 11(3), 311–316.

[6] Coelho, T., Andreoletti, G., Ashton, J. J., Batra, A., Afzal, N. A., Gao, Y., Williams, A. P., Beattie, R. M., & Ennis, S. (2016). Genes implicated in thiopurineinduced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Scientific Reports, 6(1), 34658. https://doi.org/10.1038/srep34658

[7] Collie-Duguid, E. S., Pritchard, S. C., Powrie, R. H., Sludden, J., Collier, D. A., Li, T., & McLeod, H. L. (1999). The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics, 9(1), 37–42. https://doi.org/10.1097/00008571- 199902000-00006

[8] Cooper, S. C., Ford, L. T., Berg, J. D., & Lewis, M. J. (2008). Ethnic variation of thiopurine Smethyltransferase activity: A large, prospective population study. Pharmacogenomics, 9(3), 303– 309. https://doi.org/10.2217/14622416.9.3.303

[9] Dobón Berenguer, B., Hassan, H. Y., Laayouni, H., Luisi, P., Rica no Ponce, I., Zhernakova, A., Wijmenga C., Tahir, H., Comas, D., Netea, M. G., & Bertranpetit, J. (2015). The genetics of East African populations: A Nilo-Saharan component in the African genetic landscape. Scientific Reports, 5, 9996. 2015.

[10] Hon, Y. Y., Fessing, M. Y., Pui, C. H., Relling, M. V., Krynetski, E. Y., & Evans, W. E. (1999). Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Human Molecular Genetics, 8(2), 371–376. https://doi.org/10.1093/hmg/8.2.371

[11] Lennard, L., Cartwright, C. S., Wade, R., & Vora, A. (2015). Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: The influence of thiopurine methyltransferase pharmacogenetics. British Journal of Haematology, 169(2), 228–240. https://doi.org/10.1111/bjh.13240

[12] Maitland, M. L., Vasisht, K., & Ratain, M. J. (2006). TPMT, UGT1A1 and DPYD: Genotyping to ensure safer cancer therapy? Trends in Pharmacological Sciences, 27(8), 432–437. https://doi.org/10.1016/j.tips.2006.06.007

[13] McLeod, H. L., Pritchard, S. C., Githang’a, J., Indalo, A., Ameyaw, M. M., Powrie, R. H., Booth, L., & Collie-Duguid, E. S. (1999). Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics, 9(6), 773–776. https://doi.org/10.1097/00008571- 199912000-00012

[14] Oliveira, E., Quental, S., Alves, S., Amorim, A., & Prata, M. J. (2007). Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. European Journal of Clinical Pharmacology, 63, 703–706. https://doi.org/10.1007/s00228-007-0310-8

[15] Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O’Brien, J., & Weinshilboum, R. (1997). Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clinical Pharmacology and Therapeutics, 62(1), 60–73. https://doi.org/10.1016/S0009- 9236(97)90152-1

[16] Payne, K., Newman, W., Fargher, E., Tricker, K., Bruce, I. N., & Ollier, W. E. R. (2007). TPMT testing in rheumatology: Any better than routine monitoring? Rheumatology (Oxford, England), 46(5), 727–729. https://doi.org/10.1093/rheumatology/kel427

[17] Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C. H., & Evans, W. E. (1999). Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Journal of the National Cancer Institute, 91(23), 2001–2008. https://doi.org/10.1093/jnci/91.23.2001

[18] Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M. A., Gearry, R. B., Barclay, M. L., Clark, D. W. J., Hansen, P. (2006). Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics, 24(8):767–781.

[19] Richard, V. S., Al-Ismail, D., & Salamat, A. (2007). Should we test TPMT enzyme levels before starting azathioprine? Hematology (Amsterdam, Netherlands), 12(4), 359–360. https://doi.org/10.1080/10245330701283959

[20] Schaeffeler, E., Fischer, C., Brockmeier, D., Wernet, D., Moerike, K., Eichelbaum, M., Zanger, U. M., & Schwab, M. (2004). Comprehensive analysis of thiopurine S-methyltransferase phenotypegenotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics, 14(7), 407–417. https://doi.org/10.1097/01.fpc.0000114745.08559.db

[21] Shin, J., Kayser, S. R., & Langaee, T. Y. (2009). Pharmacogenetics: From discovery to patient care. American Journal of Health-System Pharmacy, 66(7), 625–637. https://doi.org/10.2146/ajhp080170

[22] Szumlanski, C., Otterness, D., Her, C., Lee, D., Brandriff, B., Kelsell, D., Spurr, N., Lennard, L., Wieben, E., & Weinshilboum, R. (1996). Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA and Cell Biology, 15(1), 17–30. https://doi.org/10.1089/dna.1996.15.17

[23] Weinshilboum, R. M., & Sladek, S. L. (1980). Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics, 32(5), 651– 662.

[24] Woodson, L. C., Ames, M. M., Selassie, C. D., Hansch, C., & Weinshilboum, R. M. (1983, November). Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Molecular Pharmacology, 24(3), 471–478.

[25] Zeglam, H. B., Benhamer, A., Aboud, A., Rtemi, H., Mattardi, M., Saleh, S. S., Bashein, A., & Enattah, N. (2015). Polymorphisms of the thiopurine Smethyltransferase gene among the Libyan population. The Libyan Journal of Medicine, 10(1), 27053. https://doi.org/10.3402/ljm.v10.27053